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Background: Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as
potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common
type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP
(cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody
rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been
shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines;
therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the
phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse
large B-cell lymphoma.
Findings: Pretreatment with valproate at oral doses comparable to anti-convulsive therapy, resulted in upregulation
of CD20 mRNA and CD20 protein on the cell surface as measured by qPCR and FACS analysis in lymphoma biopsies
from three evaluated patients from the VALFRID study. Valproate-treatment corresponded to increased acetylation
of Histone3Lysine9 (H3K9ac) in peripheral blood mononuclear cells (PBMCs), which were employed as surrogate
tissue for valproate-related epigenetic modifications.
Conclusions: Valproate treatment at pharmacologically relevant doses resulted in upregulation of CD20 in vivo, and
also in expected epigenetic modifications. This suggests that pre-treatment with valproate or other HDACis before
anti-CD20 therapy could be advantageous in CD20-low B-cell lymphomas. Further studies are warranted to evaluate
this conclusion.
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Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive
B-cell lymphoma. Recent results show that inactivating
mutations of the histone acetyltransferases EP300 and
CREBBP, and of the histone methyltransferases MLL2 and
EZH2 occur in the majority of DLBCL cases [1-3]. Hence,
new treatments in DLBCL should aim at restoring
physiologic acetylation and methylation levels and the
use of epigenetic therapy could therefore have a rational* Correspondence: Kristina.Drott@med.lu.se
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unless otherwise stated.basis in DLBCL. At present, standard first line treat-
ment of DLBCL is chemotherapy consisting of a com-
bination of cyclophosphamide, doxorubicin, vincristine
and prednisone (CHOP). During recent years addition
of the anti-CD20 antibody rituximab has become an
international clinical standard (R-CHOP) leading to an
improved progression-free, event-free, disease-free and
overall survival. Although R-CHOP leads to remission
in 85% of patients, about 50% of these relapse, often
with disease that is resistant to rituximab [4].
A possible mechanism for resistance to antibodies tar-
geting CD20 is transcriptional downregulation of CD20
mRNA through epigenetic mechanisms [5,6]. Indeed,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hibitors such as valproate and romidepsin can increase
acetylation of the CD20 promoter resulting in recruitment
of the Sp1 transcription factor and increased expression of
CD20 mRNA and protein in B-cell lymphoma cell lines
[7]. However, to our knowledge these findings have so far
not been extended to clinical trials.
Results
Valproate upregulates CD20 expression in three diffuse
large B-cell lymphoma patients
In 2001 valproate, a gamma-aminobutyric acid (GABA)
agonist with a long history of clinical use for treatment of
epilepsy and mood disorders (reviewed in [8]), was identi-
fied having HDAC inhibitory activity. We have previously
developed an experimental model in which 48 hour pre-
treatment with valproate at pharmacological doses strik-
ingly sensitises diffuse large B-cell lymphoma cell lines to
R-CHOP induced apoptosis. Moreover, in this model the
combination of valproate and prednisolone has a synergis-
tic effect on R-CHOP-induced cell death [9]. Based on
these findings, we have initiated a phase I trial with a dose
expansion at the recommended phase II dose (VALFRID:
Valproate as First line therapy in combination with Rituxi-
mab and CHOP in Diffuse large B-cell lymphoma [10]).
VALFRID is currently on-going at three University Hospi-
tals in Sweden, and aims at including 35 patients. In this
trial valproate is administered orally three times daily prior
to R-CHOP days 1–3 as first line treatment of DLBCL pa-
tients stages II-IV. In the VALFRID trial, prednisone from
the R-CHOP regimen (75–100 mg daily) is administered
day 1–5 (together with valproate day 1–3) and rituximab,
cyclophosphamide and doxorubicin on day 3 (Table 1). In
the dose-escalation part of the study, three consenting
patients (i.e., patients 003, 008 and 010) underwent a
fine needle biopsy (FNB) from an affected lymph node
before start of valproate/prednisone on cycle 1 day 0,
and a repeated biopsy after 48-hour treatment the
morning on day 3 (i.e., before start of R-CHO). In thisTable 1 Overview of drug and sampling administration in
the VALFRID study
Day 0 1 2 3 4 5
Valproate +++ +++ +++




Valproate was administered three times daily day 1–3, prednisone was
administered day 1–5 and R-CHO (rituximab, cyclophosphamide, doxorubicin
and vincristine) was administered day 3. PBMCs were collected in the morning
day 0 and day 3 of the 1st, 3rd and 6th treatment cycles before the R-CHO
treatment was administered. Fine needle biopsy was also performed on day 0
and in the morning of day 3 before R-CHO treatment was administered in the
1st treatment cycle of consenting applicable patients.material, upregulation of CD20 protein on the cell sur-
face of lymphoma cells was assessed by flow cytometry
analysis and upregulation of CD20 mRNA by qPCR. A
representative example of the utilised flow cytometry
gating for the sorting is shown in Figure 1.
All patients were treated with pharmacologically relevant
doses of valproate comparable to those utilised in antiepi-
leptic treatment. For antiepileptic therapeutic purposes
plasma levels of 300 to 700 μM is desired [11]. In the VAL-
FRID study, valproate treatment resulted in serum levels
between 400–850 μM (please see Table 2 for doses and
serum levels of valproate in patients undergoing an FNB).
The number of bound anti-CD20 molecules per cell
surface was measured by standardizing geometric mean
fluorescence intensities (MFI) through results from a
QuantiBRITE® assay (beads covered with known quan-
tities of bound PE).
Already at a valproate dose of 30 mg/kg/day (given to pa-
tient 003) a slight increase of CD20 mRNA was measured
on day 3 (Figure 2). This was correlated to a three-fold in-
crease in CD20 molecules exposed on the cell surface
(Table 2). Valproate at 80 mg/kg/day resulted in a more
robust increase in levels of CD20 mRNA. However, the in-
crease of CD20 molecules on the cell surface was more
modest, possibly explained by the high base line expression
of CD20 on the cell surface of these patients.
Since prednisone was administered together with valpro-
ate, possible prednisone-related effects on CD20 expres-
sion were evaluated in the DLBCL cell line SU-DHL-8.
However, as shown in Figure 3, while incubation with
1 mM of valproate resulted in prompt induction of CD20
in these cells, no prednisone-related effects on either CD20
mRNA or cell surface protein were observed. This speaks
against prednisone-related effects on CD20 expression, and
supports that valproate significantly upregulates CD20 ex-
pression both on the mRNA level and on the cell surface
in diffuse large B-cell lymphoma patients.
Valproate-related effects in surrogate tissue
To assess whether the utilised doses of valproate resulted
in expected histone modifications, peripheral blood mono-
nuclear cells (PBMCs) were employed as a model. Acetyl-
ation of lysine 9 of histone H3 (H3K9ac) in PBMCs has
been suggested as an adequate surrogate tissue marker for
the HDAC inhibitory activity of valproate in tumour
cells in vivo [12]. Moreover, 5 mM valproate has been
shown to affect the tri-methylation of lysine 4 of histone
H3 (H3K4me3) in vitro [13]. Therefore, H3K9ac and
H3K4me3 were studied by Western blot in available
PBMCs from patients 001, 002, 005, 006, 007, 008, 010,
021, 023 from the VALFRID study. These patients were
treated with valproate between 30–80 mg/kg/day, result-
ing in serum levels between 400–1,000 μM (Figure 4A).
As shown in Figure 4B, valproate treatment resulted in an
Figure 1 FACS gating and CD20 expression analysis of lymphoma cells. Lymphoma cells were defined by either kappa or lambda monoclonal
CD19+/CD3- cells. Histograms of detected CD20 were used for quantification of bound anti-CD20 mAbs per cell by QuantiBRITE assay as presented in
Table 2. The figure shows the analysis of patient 008, day 0 as a representative example.
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400 μM, suggesting that levels of valproate were sufficient
to achieve expected histone acetylation. H3K4me3 was in-
creased in five patients, unchanged in one and reduced in
two patients (Figure 4C).
Although valproate has been suggested as a general
inhibitor of class I and class IIa HDACs [8], isolated
knockdown of HDAC2 mimics valproate-related effects
in preclinical models, and levels of HDAC2 have been
suggested as a relevant therapeutic target during valproate
treatment in vivo [12,14,15]. However it is not known
whether a therapeutic response to valproate treatment
correlates to up- or downregulation of HDAC2. Therefore,
levels of HDAC2 during valproate treatment of PBMCs
were monitored by Western blot but no certain conclu-
sions could be made to the HDAC2 levels in response to




MFI Bound CD20 m
per cell
003 30 2163 6866
008 80 30893 70229
010 80 35540 69096
An FNB of an affected lymph node was performed before treatment start as well as
Lymphoma cells (i.e., monoclonal B-cells) were analysed by FACS as described in m
surface was calculated by normalisation by the QuantiBRITE assay using geometric
valproate are indicated (*: Day 2).Discussion
Although the sample size is small, our data suggest that
pharmacologically relevant doses of valproate may upregu-
late CD20 expression in DLBCL patients. To our know-
ledge this has not been shown in an in vivo situation
before. Given that CD20 expression levels may be a limiting
factor for rituximab response, the results support that val-
proate pretreatment could be beneficial for the response to
anti-CD20 treatment, particularly in cases with low expres-
sion of CD20. Not only could relapsing DLBCL with low
levels of CD20 benefit from valproate treatment prior to
therapy targeting CD20, but it is also possible that valproate
treatment could enhance the efficacy of anti-CD20 anti-
bodies in chronic lymphocytic leukaemia, a B-cell lymph-
oma expressing low to intermediate levels of CD20 [16].
The doses of valproate utilised are in the range of what
is prescribed during continuous anti-epileptic treatmentll before and after valproate treatment
Day 3







morning day 3, cycle 1 in patients 003, 008 and 010 of the VALFRID study.
aterials and methods, and the number of bound CD20 antibodies to the cell

























Before valproate After valproate
Figure 2 Fold change of CD20 mRNA in lymphoma cells after valproate treatment. A fine needle biopsy of an affected lymph node was
performed before treatment start as well as morning day 3, cycle 1 in patients 003, 008 and 010 of the VALFRID study. The lymphoma cells
(i.e., monoclonal B-cells) were sorted by FACS as described in materials and methods. Levels of CD20 mRNA were estimated by qPCR. For dosage
and serum-levels of valproate, please see Table 2.
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sured by Western blot. The effect on PBMC H3K4me3
is less evident, but may still suggest clinically relevant
valproate-related effects on histone trimethylation. How-
ever, the effect of valproate on histone-methylation is prob-
ably weaker, as compared to that on histone-acetylation,
consistent with the previous notion that valproate-levels
5–10 times higher than the actual serum levels were shown
to induce histone tri-methylation in vitro [13].
The valproate administered was given together with
prednisone of the R-CHOP regimen. It cannot be ex-
cluded that this may skew the obtained results. However,
we do not observe a prednisolone-induced upregulation
of CD20 in vitro, suggesting that the observed upregula-
tion of CD20 is indeed related to valproate.
Taken together, our data suggest that administration of
valproate before anti-CD20 treatment may result in in-
creased response to anti-CD20 treatment, and also may be
feasible and safe. Indeed, this notion will be further ex-
plored in PREVAIL, a phase 0 trial on CLL patients start-
ing the fall of 2014 at Skåne University Hospital [17].
Materials and methods
Eligibility
Please see ClinicalTrials.gov: ID NCT01622439 for eligi-
bility for the VALFRID study. Informed consent was ob-
tained from patients in accordance with good clinical
practice and federal and institutional guidelines govern-
ing registered clinical trials [10]. The fine-needle biopsy
of an affected lymph node before and after valproate wasoptional, and patients 003, 008 and 010 all signed an add-
itional consent form for research on material from the
fine-needle biopsy.
Study treatment
Valproate (Ergenyl® or Orfiril®) was administered orally
every 8 hours for 3 days at doses indicated above. Pred-
nisone was administered day 1–5. R-CHO (rituximab,
cyclophosphamide, doxorubicin and vincristine) was given
after the morning dose of valproate on day 3 according to
standard protocol.
Pharmacokinetics
Levels of total plasma valproate were measured before
morning dose of valproate day 2, 3 and 4 by a
homogenous enzyme-linked immunoanalysis technique
at the Department of Clinical Chemistry at Skåne Uni-
versity Hospital.
Fine needle biopsy and FACS analysis
Prior to sample handling, QuantiBRITE® (PE) control
beads (340495, BD Biosciences) were used according to
the manufacturer’s instructions for later quantification
of bound anti-CD20 antibodies. The biopsy sample was
resuspended in NH4Cl for red blood cell lysis and
washed in PBS (5% FBS). Thereafter, filtration through a
35 μm filter (BD Biosciences) was performed. Isotype con-
trol stainings were: PE mouse IgG1 (400112-MOPC21,
BioLegend), APC mouse IgG1 (400120-MOPC21, Bio-






























































Figure 3 Effects of combination therapy with valproate and prednisolone in SU-DHL-8 cells. SU-DHL-8 cells were incubated with or
without 1 mM valproate and/or 55 μM prednisolone in cell culture media. After 48 hours, cells were harvested and levels of CD20 mRNA were
estimated by qPCR (A). Quantification of anti-CD20 antibodies bound to the cell surface was estimated using FACS and QuantiBRITE assay (B). Mean
values are from five separate experiments, bars represent standard deviation.
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Figure 4 Serum valproate levels and fold change in epigenetic biomarkers of surrogate tissue. (A) Serum valproate levels in response to
48-hour treatment of valproate. (B-D) Fold change of H3K9ac, H3K4me3 and HDAC2 expression in PBMCs as judged by Western blot. Blots were
quantified by normalising the epigenetic biomarker to the corresponding GAPDH expression and fold change determined by normalisation to
Day 0 sample. Samples are from cycle 1, 3 and 6.
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FITC anti-kappa or anti-lambda (depending on identi-
fied sample clonality on diagnostic biopsy) (F0434/
F0435, Dako), APC anti-CD3 (344812-SK7, BioLegend),
APC/Cy7 anti-CD19 (557791-SJ25C1, BD Biosciences),
PE anti-CD20 QuantiBRITE (347220-L27, BD Biosci-
ences) and DRAQ7 (abcam), added just before samples
were sorted utilizing a FACS Aria IIu (BD Biosciences)
using a 100 μm nozzle. Cell viability was assessed by
FSC/SSC and DRAQ7 showing a negligible amount of
dead cells in all samples. Using the Geometric mean of
the PE signal the number of bound CD20 antibodies per
cell was calculated using QuantiBRITE® (PE) control
beads, GraphPad Prism and Microsoft Excel software.
Sorted kappa or lambda positive populations ranged be-
tween 30,000 to 1,500,000 cells (median 300,000). Sorted
cells were resuspended in RLT+ Lysis buffer (Qiagen) with
DTT and stored at −80°C.Isolation of PBMCs
PBMCs were isolated from heparinized peripheral blood
samples by Lymphoprep according to the manufacturer’s
instructions (1114740, Axis-Shield), using RPMI-1640
(Gibco) for sample dilution. Cells were pelleted and
stored at −80°C.
Western blotting
Cells were lysed in Laemmli buffer (Bio-Rad) with β-
mercaptoethanol (Scharlau) and protease inhibitor and
phosphatase-stop (Roche). Samples were sonicated on a
Diagenode Bioruptor system (10 min), heated (99°C,
5 min) and centrifuged (4°C, 5 min) before loaded
(equivalent to 100,000 cells per well) onto precast TGX
gels (Bio-Rad). Membrane was blocked with 5% dry milk
powder solution (w/v) and then incubated with primary
and HRP-conjugated secondary antibodies in 1% block-
ing solution (w/v). Membrane was developed using ECL
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ChemiDoc XRS+ (Bio-Rad) and bands of selected epi-
genetic biomarkers were normalised via expression of
GAPDH. Fold change was determined by normalisation
to expression from day 0 samples.
Quantitative PCR
Total RNA was extracted by AllPrep Micro kit (Qiagen)
according to manufacturers protocol. Total RNA was
reversely transcribed to cDNA by MultiScript reverse
transcriptase from the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems). Quantitative
real-time PCR analysis was performed in a 20 μL reac-
tion volume containing cDNA, TaqMan Universal PCR
Master Mix (Applied Biosystems), and the probes for
CD20 (Hs00544819_m1, Life Technologies) and GAPDH
(Hs99999905, Life Technologies). The relative quantitative
method was used for analysis, and fold change was used
to present data.
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